Vitamin D Status and Respiratory Infection

The Martineau et al. individual-participant-data meta-analysis published in the BMJ in 2017, pooling 25 randomized controlled trials with more than 11,000 participants, demonstrated that Vitamin D supplementation reduces the risk of at least one acute respiratory infection (ARI) by approximately 12 percent overall. The benefit was concentrated in the deficient: participants with baseline 25-hydroxyvitamin D below 25 nmol/L (10 ng/mL) had their ARI risk reduced by roughly 70 percent when supplemented daily or weekly. Monthly or quarterly bolus dosing did not produce the benefit. The mechanism is the cathelicidin LL-37 antimicrobial peptide pathway: Vitamin D's active form (1,25-dihydroxyvitamin D) binds the Vitamin D receptor in respiratory epithelial cells and macrophages, drives transcription of cathelicidin, and arms the innate immune system against enveloped and non-enveloped respiratory viruses including influenza A and rhinovirus.

Table of Contents

  1. Mechanism — Cathelicidin LL-37 and the Vitamin D Receptor
  2. The Martineau 2017 BMJ Meta-Analysis
  3. The Urashima Schoolchildren Trial (Influenza A)
  4. Why the Benefit Concentrates in the Deficient
  5. The Seasonal Latitude Pattern
  6. Daily and Weekly Dosing vs Monthly Boluses
  7. The 25-Hydroxyvitamin D Target Range
  8. Practical Repletion Protocol
  9. Cofactors — Magnesium, K2, and Vitamin A
  10. Cautions and Upper-Limit Toxicity
  11. Key Research Papers
  12. Connections

Mechanism — Cathelicidin LL-37 and the Vitamin D Receptor

The classical model of Vitamin D (calcium absorption and bone mineralization) does not begin to explain its respiratory-infection effect. The respiratory mechanism operates through a fundamentally different pathway, characterized in detail by Philip Liu, Robert Modlin, and colleagues at UCLA in a landmark 2006 Science paper.

The pathway works as follows.

  1. An invading pathogen (bacterial cell wall component, viral RNA, etc.) is detected by a respiratory epithelial cell or alveolar macrophage via toll-like receptor (TLR) signaling, particularly TLR2.
  2. TLR signaling upregulates both the Vitamin D receptor (VDR) and the CYP27B1 enzyme (which converts circulating 25-hydroxyvitamin D to its active 1,25-dihydroxyvitamin D form) in the responder cell.
  3. If sufficient circulating 25-hydroxyvitamin D is available as substrate, the cell produces active 1,25-D locally.
  4. 1,25-D binds the upregulated VDR, the VDR-RXR heterodimer translocates to the nucleus, and binds Vitamin D response elements (VDREs) in the promoters of innate-immune genes — most importantly, the cathelicidin antimicrobial peptide (CAMP) gene.
  5. The cell secretes cathelicidin LL-37, a 37-amino-acid antimicrobial peptide with broad activity against bacteria, enveloped viruses (including influenza A), and non-enveloped viruses (including rhinovirus). LL-37 disrupts microbial membranes, neutralizes endotoxin, and chemoattracts additional immune cells.

The clinical implication is that this entire cascade requires circulating 25-hydroxyvitamin D as substrate. A patient with serum 25-hydroxyvitamin D below 20 ng/mL has insufficient substrate to mount the LL-37 response when their respiratory epithelium is challenged. A patient with serum 25-hydroxyvitamin D in the 40–60 ng/mL range has plenty of substrate. The Martineau and Urashima trials demonstrate exactly this dose-response: the benefit is large in the deficient and small in the replete.

Back to Table of Contents

The Martineau 2017 BMJ Meta-Analysis

The Martineau et al. 2017 BMJ meta-analysis is the single most influential modern paper on Vitamin D and respiratory infection. It is methodologically strong for three reasons.

  1. Individual-participant data (IPD) rather than aggregate trial data. The authors contacted the original investigators of 25 randomized trials and obtained the individual-patient datasets, allowing subgroup analyses that would have been impossible with summary-level data alone.
  2. Pre-registered analysis plan. The subgroup analyses (baseline 25-D status, dosing frequency, age) were declared in advance, not discovered post hoc.
  3. Sample size. 11,321 participants across 25 trials, ages 0 to 95.

Headline findings.

The dosing-frequency finding is mechanistically explainable. A single 100,000 IU bolus produces a transient 25-D spike followed by feedback suppression of the activating enzyme (CYP27B1) and induction of the inactivating enzyme (CYP24A1). The net effect can actually impair local 1,25-D synthesis in tissue for weeks. Daily 1,000–4,000 IU produces a stable serum 25-D level without triggering the regulatory backlash.

Back to Table of Contents

The Urashima Schoolchildren Trial (Influenza A)

The 2010 Urashima et al. trial published in the American Journal of Clinical Nutrition was one of the first high-quality randomized trials specifically testing Vitamin D for influenza prevention. Japanese schoolchildren (n=334) were randomized to 1,200 IU/day Vitamin D3 or placebo during the December-March influenza season.

Results.

The Urashima trial is one of several pieces of evidence (along with Camargo et al. 2012 in Mongolian children and Aloia & Li-Ng 2007 in postmenopausal African-American women) that established the influenza-specific signal for Vitamin D supplementation. Subsequent larger trials (VIDARIS in New Zealand, VITAL substudies, and Jolliffe's 2021 update of the Martineau meta-analysis) have been mixed in single studies but consistent in pooled analyses.

Back to Table of Contents

Why the Benefit Concentrates in the Deficient

The Martineau IPD analysis showed a dramatic concentration of benefit in the most deficient participants — a 70% reduction in ARI risk at baseline 25-D <10 ng/mL versus a 25% reduction in those above. This pattern has a clean mechanistic interpretation.

The LL-37 cathelicidin pathway is substrate-limited at low circulating 25-D. Once 25-D is in the sufficient range (commonly cited as >30 ng/mL by the Endocrine Society, with optimal often described as 40–60 ng/mL), additional substrate provides no further benefit because the rate-limiting step is elsewhere (typically TLR signaling, VDR expression, or CYP27B1 activity, not substrate availability).

The clinical implication is twofold.

This is why the Vitamin D answer to "should I supplement to prevent colds and flu?" depends entirely on a blood test result. The intervention that benefits the deficient person dramatically does little for the replete person.

Back to Table of Contents

The Seasonal Latitude Pattern

The most striking population-level evidence for the Vitamin D / respiratory-infection link is the seasonal pattern of influenza incidence at temperate latitudes. Influenza is a winter disease in the northern hemisphere (peaking December through March) and a winter disease in the southern hemisphere (peaking June through September). At the equator, where seasonal Vitamin D variation is minimal, influenza is endemic year-round without strong seasonal peaks.

John Cannell and colleagues advanced this observation into a coherent hypothesis in a 2006 Epidemiology and Infection paper. The hypothesis is that the winter dip in cutaneous Vitamin D synthesis (UVB-driven, requires solar zenith angle above approximately 35°) drives population-level 25-D deficiency, which in turn drives population-level susceptibility to influenza and other respiratory infections that are circulating year-round. The viral pathogen is always present; the host immune competence varies seasonally with sunlight exposure.

Multiple lines of evidence support this hypothesis: (1) clinical trial benefit concentrated in deficient patients, (2) the seasonal pattern in temperate latitudes, (3) the equatorial absence of strong seasonality, (4) the documented winter 25-D nadir in northern populations (typically 30–50% lower than summer peak), and (5) the experimental cathelicidin mechanism.

Back to Table of Contents

Daily and Weekly Dosing vs Monthly Boluses

The Martineau IPD meta-analysis identified one critical practical finding: daily or weekly Vitamin D dosing protected against ARI; monthly or larger bolus dosing did not. This finding has been independently replicated and is now widely accepted.

The mechanism is regulatory. The body normally maintains a tight feedback loop on Vitamin D metabolism:

A single 100,000–300,000 IU bolus produces a transient serum 25-D spike that triggers the CYP24A1 inactivation cascade. For weeks afterward, even when serum 25-D is still in the optimal range numerically, local 1,25-D production in respiratory tissue is suppressed, the cathelicidin response is impaired, and respiratory-infection susceptibility is paradoxically higher than baseline.

The practical implication is to dose daily (or at most weekly), never monthly or quarterly. Daily 2,000–5,000 IU D3 produces stable serum 25-D in the optimal range without triggering the regulatory backlash, and is the format used in the trials that showed benefit.

Back to Table of Contents

The 25-Hydroxyvitamin D Target Range

The official institutional ranges vary by organization.

For the specific respiratory-infection endpoint, the Martineau IPD analysis suggests:

The pragmatic target for the typical adult is 40–60 ng/mL, achievable in most northern adults with daily 2,000–5,000 IU D3 plus seasonal sun exposure. Confirm with a 25-hydroxyvitamin D blood test before and after starting supplementation; the test is widely available (Quest, LabCorp), costs $30–$80 cash-pay, and produces a clear number to act on.

Back to Table of Contents

Practical Repletion Protocol

Baseline assessment

  1. Order a 25-hydroxyvitamin D blood test. This is the right test — not 1,25-dihydroxyvitamin D, which is tightly regulated and not a reliable marker of status.
  2. If your value is below 30 ng/mL, you have headroom for benefit.

Repletion dose

Form and timing

Back to Table of Contents

Cofactors — Magnesium, K2, and Vitamin A

Vitamin D does not operate in isolation. Three cofactors materially affect its function.

Magnesium

Magnesium is required as a cofactor for every enzyme in the Vitamin D metabolic pathway: the hydroxylases that convert D3 to 25-D in the liver, the activating enzyme CYP27B1 that converts 25-D to 1,25-D in tissue, and the VDR itself (which requires magnesium for ligand binding). Magnesium-deficient patients can take Vitamin D supplements and never raise their serum 25-D appropriately because the activation enzymes are not functional. If you are supplementing Vitamin D and your serum 25-D is not rising as expected, suspect magnesium deficiency first. Typical adjunct: 200–400 mg/day magnesium glycinate or citrate, ideally separated from Vitamin D by a few hours.

Vitamin K2

Vitamin D drives calcium absorption from the gut. Vitamin K2 (MK-4 and MK-7 forms) activates the proteins (osteocalcin, matrix Gla protein) that direct absorbed calcium into bone and away from soft tissue / arterial wall. High-dose Vitamin D supplementation without K2 may contribute to arterial calcification in some individuals over years. Co-supplementation with K2-MK7 (90–180 mcg/day) is commonly recommended at Vitamin D doses above 2,000 IU/day.

Vitamin A

The VDR and the RAR (retinoic acid receptor, activated by Vitamin A's active form) both heterodimerize with the same partner — RXR (retinoid X receptor). At extreme levels of either vitamin, competition for RXR becomes a factor and the two systems antagonize each other. At physiological levels of both, they cooperate. The practical implication is to avoid massive imbalances — do not take 30,000 IU/day Vitamin A while taking 50,000 IU/day Vitamin D and expect either to work normally.

Back to Table of Contents

Cautions and Upper-Limit Toxicity

Vitamin D toxicity is uncommon but real. The toxic syndrome is hypercalcemia, with confusion, weakness, polyuria, kidney stones, and potentially soft-tissue calcification.

Back to Table of Contents

Key Research Papers

  1. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017 — PubMed 28202713
  2. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol 2021 — PubMed 33798465
  3. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010 — PubMed 20219962
  4. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006 — PubMed 16497887
  5. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006 — PubMed 16959053
  6. Camargo CA Jr, Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics 2012 — PubMed 22945407
  7. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect 2007 — PubMed 17352841
  8. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009 — PubMed 19237723
  9. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2013 — PubMed 23840281
  10. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011 — PubMed 21263449
  11. Goodall EC, Granados AC, Luinstra K, et al. Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. BMC Infect Dis 2014 — PubMed 24655428
  12. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. J Pharmacol Pharmacother 2012 — PubMed 23129956

Back to Table of Contents

Connections

Back to Table of Contents